News coverage about Vision Sciences (NASDAQ:CGNT) has trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vision Sciences earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 43.7920504117832 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
CGNT has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Vision Sciences from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Monday, April 2nd. Roth Capital lowered shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Friday, March 23rd. Finally, Aegis lowered shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.75 price target for the company. in a research note on Tuesday, March 13th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $4.50.
Get Vision Sciences alerts:Shares of NASDAQ:CGNT remained flat at $$3.85 during trading on Friday. The stock has a market capitalization of $234.49 million, a P/E ratio of -385.00 and a beta of 0.58. Vision Sciences has a 12 month low of $1.55 and a 12 month high of $3.92.
Vision Sciences (NASDAQ:CGNT) last released its earnings results on Friday, March 30th. The medical device company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. Vision Sciences had a negative net margin of 1.57% and a negative return on equity of 1.39%. The business had revenue of $15.54 million for the quarter, compared to the consensus estimate of $15.49 million. equities analysts forecast that Vision Sciences will post 0.01 earnings per share for the current year.
Vision Sciences Company Profile
Cogentix Medical, Inc, a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use.
No comments:
Post a Comment